BONE REMODELING MARKERS AS PREDICTORS OF BONE METABOLIC CHANGES IN MALES WITH DIABETIC OSTEOPATHY

Diabetic osteopathy is one of the little studied complications of diabetes mellitus (DM), which leads to common lowtrauma fractures and, as a consequence, disability and death. The level of insulin is connected with bone functional and morphological changes followed by decreased bone mineral density (BMD) in the early stages of diabetic osteopathy.
Objective: to study bone morphofunctional properties in males with type 1 and 2 DM (T1DM and T2DM).
Subjects and methods. Examinations were made in 41 male patients with T1DM and 52 male patients with T2DM without a history of fractures. Their age varied from 40 to 70 years (mean age, 55.8±0.7 years and 58.4±0.9 years, respectively). A control group consisted of 34 patients (mean age, 55.9±0.9 years) without a history of DM. Patients with other endocrine disorders, end-stage complications, or chronic liver and kidney diseases were excluded from the investigation. BMD was determined by dual-energy X-ray absorptiometry (DXA). Serum bone remodeling markers (procollagen type 1 amino-terminal propeptide and C-terminal telopeptide), as well as 25(OH)D, parathyrin, insulin, glycated hemoglobin (HbA1c), and electrolytes (Ca2+, P+) were evaluated.
Results and discussion. An association of BMD with renal function, HbA1c, and body mass index was observed in patients with T2DM. In the T1MD group, BMD was closely related to insulin deficiency and was significantly lower than that in the control group. In patients with vitamin D deficiency, BMD was significantly lower than in those with normal vitamin D levels (p<0.05). The patients with T1DM displayed both a decrease in BMD (p<0.05) and a pronounced change in the levels of bone markers (p<0.05). Those with T2DM had impaired bone remodeling processes, which was determined by the level of these markers (p<0.05) and observed in the presence of normal BMD due to the complex pathophysiology of the underlying disease.
Conclusion. Vitamin D deficiency, insufficient and decreased insulin sensitivity, hyperglycemia, and overweight are important causes of osteopathy in patients with DM. The markers of bone remodeling may become promising indicators for diagnosing osteopathy, but additional studies are needed to elaborate recommendations for their use in routine practice in order to predict and prevent this complication of DM.

1. American Diabetes A. Standards of medical care in diabetes – 2018 Abridged for Primary Care Providers. Clin Diabet. 2018;36(1):14-37. doi: 10.2337/cd17-0119

2. International Diabetes Federation. Diabetes Atlas 2015: executive summary. 7th ed. Brussels: IDF; 2015.

3. Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, et al. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20(9):2009-17. doi: 10.1681/ASN.2008121258

4. Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014;29(4):787-95. doi: 10.1002/jbmr.2106

5. Farlay D, Armas LA, Gineyts E, et al. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31(1):190-5. doi: 10.1002/jbmr.2607

6. Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone. 2016;82:28-34. doi: 10.1016/j.bone.2015.07.027

7. Sanches CP, Vianna AGD, Barreto FC. The impact of type 2 diabetes on bone metabolism. Diabetol Metab Syndr. 2017;9:85. doi:10.1186/s13098-017-0278-1

8. Diaz P, Barajas GS, Hernandez-Flores ZG, et al. The impact of vitamin D levels on glycemic control and bone mineral density in postmenopausal women with type 2 diabetes. J Endocrinol Invest. 2015;38(12):1365-72. doi: 10.1007/s40618-015-0394-4

9. Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64:1043-53. doi: 10.1507/endocrj.EJ17-0323

10. Epstein S, Defeudis G, Manfrini S, et al. Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. Osteoporos Int. 2016;27:1931-51. doi: 10.1007/s00198-015-3454-x

11. Ahmed N. Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3- 21. doi: 10.1016/j.diabres.2004.09.004

12. Chaiban JT, Nicolas KG. Diabetes and bone: still a lot to learn. Clin Rev Bone Miner Metab. 2015;13(1):20-35. doi: 10.1007/s12018-015-9178-9

13. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr. 2004;79:820-5. doi: 10.1093/ajcn/79.5.820

14. De Liefde II, van der Klift M, De Laet CEDH, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int. 2005;16:1713-20. doi: 10.1007/s00198-005-1909-1

15. Li Y, Liu H, Sato Y. The Association between the serum C-peptide level and bone mineral density. PLoS ONE. 2013;8(12):e83107. doi: 10.1371/journal.pone.0083107

16. Moreira CA, Barreto FC, Dempster DW. New insights on diabetes and bone metabolism. J Bras Nefrol. 2015;37(4):490-5. doi: 10.5935/0101-2800.20150077

17. Oei L, Rivadeneira F, Zillikens MC, Oei EHG. Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 2015;13(2):106-15. doi: 10.1007/s11914-015-0260-5

18. Paschou SA, Dede AD, Anagnostis PG, et al. Type 2 diabetes and osteoporosis: a guide to optimal management. J Clin Endocrinol Metab. 2017;102(10):3621-34. doi: 10.1210/jc.2017-00042

19. Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep. 2015;13(3):186-91. doi: 10.1007/s11914-015-0265-0

20. Liao C-C, Lin C-S, Shih C-C, et al. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37:2246-52. doi: 10.2337/dc13-2957

21. Hernandez CJ, Tang SY, Baumbach BM, et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone. 2005;37(6):825-32. doi: 10.1016/j.bone.2005.07.019